

AN EARLY WARNING SYSTEM FOR CARDIOVASCULAR DISEASE



Good for your patients. Good for your practice.

Using the **AngioDefender**™ system to complement your patients' care routine enables you to:



Improve your patient management decisions.

Identify early-stage CVD in asymptomatic patients and monitor the effectiveness of prescription therapy and lifestyle modification.



Provide quick, accurate assessments.

Non-invasive and easy to use, the AngioDefender™ test takes under 20 minutes and delivers accurate, reproducible results.




Encourage repeat visits.

Measure your patients' progress and engage in ongoing, productive conversations about heart health.




Offer a test that other practitioners do not.

Attract new, health-conscious patients by being among the first to offer AngioDefender™ testing.



PREDICT CARDIOVASCULAR DISEASE BEFORE SYMPTOMS APPEAR


Clinical studies have demonstrated that endothelial cell dysfunction is a key biomarker of atherosclerosis and cardiovascular disease (CVD). In fact, a patient's level of endothelial dysfunction can predict the occurrence of CVD years in advance, even when a patient does not currently exhibit symptoms. This is because endothelial damage leads to thickening of the blood vessels, resulting in a measurable reduction of arterial compliance during the early stages of CVD.



level of endothelial dysfunction early on, allowing time for behavioral and pharmacologic intervention to protect the endothelium from further damage.

MEASURING ENDOTHELIAL DYSFUNCTION BY ANGIODEFENDER™

The endothelium is the single-cell-thick interior lining of all blood vessels in the body. Dilation of blood vessels is enabled by endothelial cells, which release vasodilators like nitric oxide (NO) in response to increased blood flow.



The percentage of difference in diameter between fully dilated and resting blood vessels is known as flow-mediated dilation (%FMD). Healthier vessels release more NO, leading to a higher %FMD and a lower risk of CVD and atherosclerosis. AngioDefender measures these sensitive changes, then calculates and converts them into a %FMD score.

HOW THE ANGIODEFENDER™ SYSTEM WORKS

To measure %FMD, the device runs through a series of inflations and deflations to analyze the endothelium's response to increased blood flow. Then, by combining the principles of blood pressure, pulse wave analysis, and a proprietary data analysis algorithm, the AngioDefender™ system produces a unique %FMD score in just minutes.



The AngioDefender™ system accurately and reproducibly quantifies %FMD without the need for expensive ultrasound equipment or operator expertise.


EARLIER DETECTION, HEALTHIER OUTCOMES

How would your practice change if you could predict CVD in patients before symptoms appear? Before an EKG or angiogram is administered? Even before lab tests are performed? Use AngioDefender™ to:

- + Evaluate CVD risk
- + Monitor treatments
- + Assess interventions

The following behavioral and pharmacological interventions have been clinically shown to reduce several CVD risk factors and positively affect endothelial function.

CVD RISK FACTOR	INTERVENTION/TREATMENT
High BMI	Exercise, diet modification
Diabetes	Glycemic control
Tobacco smoking	Smoking cessation
High cholesterol	Exercise, diet modification
	Lipid-lowering therapy (i.e., statins)
Hypertension	Exercise, diet modification
	Antihypertensives (i.e., ACE inhibitors)
Sleep Apnea	CPAP device





Visit **closingthegap.ca/angiodefender** to learn more about incorporating the AngiotDefender™ system into your practice.

The **AngioDefender™** system is the most effective solution to the technical, clinical, usability, and cost challenges associated with detecting early endothelial dysfunction.

Visit **closingthegap.ca/angiodefender** to learn more about incorporating the AngioDefender™ system into your practice.



Servicing Locations Across Ontario. Call today to find out more 1-877-560-0202



